- These are ideas and opinion only; always do you own due diligence
- NASDAQ: INSM +119.61% on positive data of Phase 3 study.
- These two have Phase 3 data in September
- #AXON– MINDSET Phase 3 study results in late September 2017 http://investors.axovant.com/news-releases/news-release-details/axovant-announces-fiscal-first-quarter-financial-results-and
- There are no current treatment for Alzheimer’s disease, expect stock to make big move depending on data results.
2. #VSAR report topline data from the pediatric Phase 3 VELOCITY trial around the end of September http://ir.versartis.com/releasedetail.cfm?ReleaseID=1034802&corpSection=NR
Thanks for reading. Goodluck. ~PT365